Selonterra, Inc. is a San Francisco Bay Area venture capital funded Delaware corporation. Selonterra fundamentally transforms therapeutic approaches to neurodegenerative disorders, including Alzheimer’s disease, by a rigorous exploitation of our novel insights into the genetic causes of disease. Selonterra discovered that the altered DNA of genetic variants associated with neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease, affect transcription factor binding sites and thereby change the expression of genes nearby. In our Alzheimer’s disease program we develop small molecules that modulate the function of an unexploited, druggable target and will fundamentally change Alzheimer’s disease therapy. We built a global network of specialized collaborator companies and apply state-of-the art technologies to execute our program capital efficiently.